Loading
HKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$20.84
−HK$0.40 · -1.88%
Livzon Pharmaceutical Group Inc., founded in Zhuhai, China, in 1985, is a prominent enterprise dedicated to the research, development, manufacturing, and global commercialization of a wide range of pharmaceutical products, including finished drugs, active pharmaceutical ingredients (APIs), and intermediate chemical compounds. The company's extensive therapeutic portfolio features numerous specialized medications, such as Ilaprazole enteric coated tablets for treating duodenal ulcers and reflux esophagitis, and Laprazole sodium injections designed to manage peptic ulcer hemorrhage. Other key pharmaceutical offerings include Leuprorelin Acetate Microspheres for injection, Urofollitropin injections for anovulation, Perospirone Hydrochloride for schizophrenia treatment, Anti-viral Granules for combating upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, sweating, and vertigo, and is also applied in managing symptoms for lung and stomach cancer patients. Beyond therapeutics, Livzon also excels in producing diagnostic reagents. Its diagnostic kits include those for detecting IgM/IgG antibodies to coronavirus, nucleic acid test kits for human immunodeficiency virus type 1, antinuclear antibody tests, interferon-gamma release assays, and rapid tests for Mycoplasma pneumoniae IgM antibodies. Furthermore, the company's comprehensive product line encompasses biochemical drugs, microbiological preparations, biologics, traditional Chinese medicinal preparations, pharmaceutical raw materials, and antibiotics.
Latest quote
HK$20.84
−HK$0.40 · -1.88%
Regular session · HKT · Market data may be delayed.
Livzon Pharmaceutical Group Inc., founded in Zhuhai, China, in 1985, is a prominent enterprise dedicated to the research, development, manufacturing, and global commercialization of a wide range of pharmaceutical products, including finished drugs, active pharmaceutical ingredients (APIs), and intermediate chemical compounds. The company's extensive therapeutic portfolio features numerous specialized medications, such as Ilaprazole enteric coated tablets for treating duodenal ulcers and reflux esophagitis, and Laprazole sodium injections designed to manage peptic ulcer hemorrhage. Other key pharmaceutical offerings include Leuprorelin Acetate Microspheres for injection, Urofollitropin injections for anovulation, Perospirone Hydrochloride for schizophrenia treatment, Anti-viral Granules for combating upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, sweating, and vertigo, and is also applied in managing symptoms for lung and stomach cancer patients. Beyond therapeutics, Livzon also excels in producing diagnostic reagents. Its diagnostic kits include those for detecting IgM/IgG antibodies to coronavirus, nucleic acid test kits for human immunodeficiency virus type 1, antinuclear antibody tests, interferon-gamma release assays, and rapid tests for Mycoplasma pneumoniae IgM antibodies. Furthermore, the company's comprehensive product line encompasses biochemical drugs, microbiological preparations, biologics, traditional Chinese medicinal preparations, pharmaceutical raw materials, and antibiotics.
Day range
Current HK$20.84
52-week range
Current HK$20.84
Regular session · HKT · Market data may be delayed.
Livzon Pharmaceutical Group Inc., founded in Zhuhai, China, in 1985, is a prominent enterprise dedicated to the research, development, manufacturing, and global commercialization of a wide range of pharmaceutical products, including finished drugs, active pharmaceutical ingredients (APIs), and intermediate chemical compounds. The company's extensive therapeutic portfolio features numerous specialized medications, such as Ilaprazole enteric coated tablets for treating duodenal ulcers and reflux esophagitis, and Laprazole sodium injections designed to manage peptic ulcer hemorrhage. Other key pharmaceutical offerings include Leuprorelin Acetate Microspheres for injection, Urofollitropin injections for anovulation, Perospirone Hydrochloride for schizophrenia treatment, Anti-viral Granules for combating upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, sweating, and vertigo, and is also applied in managing symptoms for lung and stomach cancer patients. Beyond therapeutics, Livzon also excels in producing diagnostic reagents. Its diagnostic kits include those for detecting IgM/IgG antibodies to coronavirus, nucleic acid test kits for human immunodeficiency virus type 1, antinuclear antibody tests, interferon-gamma release assays, and rapid tests for Mycoplasma pneumoniae IgM antibodies. Furthermore, the company's comprehensive product line encompasses biochemical drugs, microbiological preparations, biologics, traditional Chinese medicinal preparations, pharmaceutical raw materials, and antibiotics.
Day range
Current HK$20.84
52-week range
Current HK$20.84
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 12.02B CNY | 11.81B CNY | 12.43B CNY | 12.63B CNY | 12.06B CNY |
| Cost of goods sold | 4.1B CNY | 4.08B CNY | 4.77B CNY | 4.46B CNY | 4.25B CNY |
| Gross profit | 7.92B CNY | 7.73B CNY | 7.66B CNY | 8.17B CNY | 7.81B CNY |
| Research and development | 821.02M CNY | 1.03B CNY | 1.33B CNY | 1.43B CNY | 1.15B CNY |
| Selling, general, and administrative | 3.3B CNY | 2.97B CNY | 4.25B CNY | 4.54B CNY | 4.13B CNY |
| Operating expenses | 4.97B CNY | 4.89B CNY | 5.24B CNY | 5.93B CNY | 5.62B CNY |
| Interest income | 290.48M CNY | 247.96M CNY | 368.16M CNY | 315.14M CNY | 162.19M CNY |
| Interest expense | 60.14M CNY | 88.61M CNY | 102.09M CNY | 97.55M CNY | 84M CNY |
| Depreciation and amortization | 539.01M CNY | 575.14M CNY | 840.32M CNY | 652.32M CNY | 445.27M CNY |
| Operating income | 2.95B CNY | 2.84B CNY | 2.42B CNY | 2.35B CNY | 2.27B CNY |
| Net income | 2.02B CNY | 2.06B CNY | 1.95B CNY | 1.91B CNY | 1.78B CNY |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$1.1988
2025 complete year-20.4% since 2021
2026 partial: HK$1.643
HK$1.5058
2,021
HK$1.5116
2,022
HK$1.7439
2,023
HK$1.482
2,024
HK$1.1988
2,025
HK$1.643
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
DividendUpcoming | Oct 13, 2026 | HK$1.1924Special | Oct 15, 2026 | Nov 3, 2026 |
Dividend | Jun 16, 2026 | HK$1.643Annual | Jun 17, 2026 | Jul 13, 2026 |
Dividend | Jun 13, 2025 | HK$1.1988Annual | Jun 16, 2025 | Jul 11, 2025 |
Dividend | Jul 8, 2024 | HK$1.482Annual | Jul 9, 2024 | Aug 5, 2024 |
Dividend | Jul 4, 2023 | HK$1.7439Annual | Jul 5, 2023 | Jul 31, 2023 |
Dividend | May 30, 2022 | HK$1.5116Annual | Jun 1, 2022 | Jun 24, 2022 |
Ex-dividend Oct 13, 2026
HK$1.1924
Special
Record Oct 15, 2026 · Payment Nov 3, 2026
Ex-dividend Jun 16, 2026
HK$1.643
Annual
Record Jun 17, 2026 · Payment Jul 13, 2026
Ex-dividend Jun 13, 2025
HK$1.1988
Annual
Record Jun 16, 2025 · Payment Jul 11, 2025
Ex-dividend Jul 8, 2024
HK$1.482
Annual
Record Jul 9, 2024 · Payment Aug 5, 2024
Ex-dividend Jul 4, 2023
HK$1.7439
Annual
Record Jul 5, 2023 · Payment Jul 31, 2023
Ex-dividend May 30, 2022
HK$1.5116
Annual
Record Jun 1, 2022 · Payment Jun 24, 2022
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard FTSE Emerging Markets ETFVWO7.08M0.00%162.3B USD0.06%$60.87-0.59%
Vanguard Total International Stock ETFVXUS6.74M0.00%646.2B USD0.05%$87.41-0.76%
JPMorgan International Value ETFJIVE4.78M0.12%4.01B USD0.55%$98.76-0.52%
State Street SPDR Portfolio Emerging Markets ETFSPEM1.63M0.01%18.03B USD0.07%$52.97-0.62%
Vanguard FTSE All-World ex-US ETFVEU1.23M0.00%95.9B USD0.04%$85.39-0.78%
WisdomTree Emerging Markets SmallCap Dividend FundDGS835.62K0.05%1.78B USD0.58%$64.91-0.23%
Vanguard International High Dividend Yield ETFVYMI767.67K0.00%21.9B USD0.07%$105.35-0.80%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM562.58K0.01%9.76B USD0.39%$40.92-0.05%Vanguard FTSE Emerging Markets ETFVWOVanguard Total International Stock ETFVXUSJPMorgan International Value ETFJIVEState Street SPDR Portfolio Emerging Markets ETFSPEMVanguard FTSE All-World ex-US ETFVEUWisdomTree Emerging Markets SmallCap Dividend FundDGSVanguard International High Dividend Yield ETFVYMIDimensional - Emerging Markets Core Equity 2 ETFDFEMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
